


Journal Pre-proof

New paradigm of B cell biology regarding the elucidation of a new mechanism of tissue fibrosis in IgG4-related disease.

Hiroshi Nakase, MD, PhD, Keisuke Ishigami, MD, PhD.



PII: S0091-6749(20)30038-5

DOI: <https://doi.org/10.1016/j.jaci.2020.01.004>

Reference: YMAI 14368

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 30 September 2019

Revised Date: 25 December 2019

Accepted Date: 2 January 2020

Please cite this article as: Nakase H, Ishigami K, New paradigm of B cell biology regarding the elucidation of a new mechanism of tissue fibrosis in IgG4-related disease., *Journal of Allergy and Clinical Immunology* (2020), doi: <https://doi.org/10.1016/j.jaci.2020.01.004>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.

New paradigm of B cell biology regarding the elucidation of a new mechanism of tissue fibrosis in IgG4-related disease.

Hiroshi Nakase, MD, PhD, Keisuke Ishigami, MD, PhD.

Correspondence to: Hiroshi Nakase, MD, PhD

Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine,

S-1, W-16, Chuoku, Sapporo, Hokkaido, 060-8543, Japan

Telephone: +81-11-611-2111

Fax: +81-11-613-1241

Email: hiropynakase@gmail.com

Disclosure of all funding sources

No conflict of interest

Key Words: plasmablast, PDGF-B, LOXL2, CD4 T cells, fibrosis.

Fibrosis, which occurs in many organs including the lung, liver, kidney, and pancreas, is defined as an excessive deposition of extracellular matrix (ECM), which leads to the destruction of organ structure and impairment of organ function. Multiple immune and molecular pathways are involved in the pathophysiology of fibrosis. Many researchers have focused on the involvement of various types of immune cells, including CD4 T cells, dendritic cells, macrophages and mast cells, in tissue fibrosis (1). Unfortunately, despite extensive studies regarding the contribution of these cells to tissue fibrosis, experimental data have not been successfully translated to clinical application.

IgG4-related disease (IgG4-RD) is a systemic condition of unknown cause characterized by highly fibrotic lesions, with dense lymphoplasmacytic infiltrates containing a preponderance of IgG4-expressing plasma cells. CD4⁺ T cells and B cells constitute the major inflammatory cell populations in IgG4-RD lesions. Among the CD4⁺ T-cell subsets, T follicular helper (fh) cells, which provide help to B cells during T cell-dependent immune responses and contribute to the processes of isotype switching, are considered to contribute to IgG4-RD pathogenesis. Akiyama et al. reported a potential role of circulating Tfh2 cells in IgG4-RD. Recently, it was found that in IgG4-RD, specific CD4⁺ CTLs clonally expand, infiltrate disease sites and are reactivated locally, presumably by activated cognate B cells that capture the driving antigen through the BCR, internalize it and present it to the CD4⁺ CTLs, causing them to drive the inflammatory and fibrotic processes that characterize the disease (2).

Since their discovery approximately 50 years ago, B cells have been largely recognized as being active in antibody-dependent immune responses. Interestingly, recent studies indicate that B cells appear to have an antibody-independent role and appear to be one of the emerging important players regarding tissue fibrosis because several animal studies have shown that B cell depletion ameliorated fibrosis in

lung, liver, and kidney models (1). It is well known that IgG4-RD is characterized by a fibroinflammatory condition with tissue fibrosis. Typical presentation and imaging findings include mass-forming synchronous or metachronous lesions in almost any organ, but most commonly in the pancreas, bile duct, retroperitoneum, kidneys, lungs, salivary and lacrimal glands, orbit, and lymph nodes (3).

Generally, one of the most important processes of the observed pathological features of IgG4-RD is the induction of a polarized CD4⁺ T-cell population, which activates innate immune cells (including macrophages, myofibroblasts, and fibroblasts) to drive fibrosis, which could involve the collaboration of activated B-lineage cells, possibly expanding plasmablasts that enter the damaged tissue along with activated CD4⁺ T cells (4). The initial rationale for rituximab treatment for immune mediated diseases has been to blunt the effects of disease-associated autoantibodies. For example, B lymphocyte depletion by rituximab is effective for pemphigus vulgaris in which the autoimmune condition is mediated by IgG4 autoantibodies (5). In IgG4-related disease, total IgG4 has been used as a surrogate for autoantibody levels and rapid decline in serum IgG4 levels associated with prompt clinical improvement has been demonstrated in the clinical trial of Khosroshahi et al as well as Carruthers study. (6, 7)

In this regard, mechanistic studies on patients with IgG4-RD treated with rituximab should lead to novel insights about the pathophysiology of the disease; however, there has been no direct evidence supporting the possible mechanism of B cell involvement in the tissue fibrosis of IgG4-RD.

In an issue of the Journal of Allergy Clinical Immunol, Della-Torre et al reported the direct contribution of B lymphocytes to tissue fibrosis in patients with IgG4-RD (8). Of note, they provided the first evidence that plasmablasts (which the authors focused on as a population with major involvement in IgG4-RD

pathophysiology) represent a B cell subset with intrinsic fibrogenic potential in IgG4-RD in contrast to both naïve and memory B cells.

First, they cocultured primary human fibroblasts with CD19⁺ B cells (naïve, memory and plasmablast) isolated from the peripheral blood of patients with IgG4-RD and examined the profibrotic gene expression and collagen production of the cultured fibroblasts by transcriptomic analyses. The data revealed that B cells from patients with IgG4-related autoimmune pancreatitis induced the activation of profibrotic pathways in the cocultured fibroblasts, with a significant upregulation of genes involved in epithelial-mesenchymal transition as well as increased collagen production compared to that in control fibroblasts. Second, they examined soluble profibrotic molecules secreted from B lymphocytes that contribute to the development of fibrosis by a Luminex-based approach. Interestingly, coculture of B cells from healthy controls with fibroblasts was also associated with increased collagen secretion; however, the amount of this secretion was less than that of the coculture with IgG4-RD B cells. Additionally, both B cells from patients with IgG4-RD and healthy controls could induce platelet-derived growth factor (PDGF)-B, CCL4, CCL5, and CCL11. Among these molecules, PDGF-B most biologically contributed to B lymphocyte-dependent collagen production from human fibroblasts, which was confirmed by PDGF-B blockade examination. Moreover, in an in vivo study, the authors showed that not only B cells but also alpha-SMA⁺ myofibroblasts produced PDGF B, CCL4, CCL5, and CCL11. Overall, both cells could drive inflammation in the affected lesions by orchestrating these molecules, which finally leads to tissue fibrosis.

The question is why the collagen production induced by B cells from patients with IgG4-RD was significantly higher than that from a healthy donor despite similar levels of PDGF-B in the supernatants.

A previous study demonstrated a significant correlation between the expansion of plasmablasts in

patients with IgG4-RD and serological markers as well as decreasing plasmablasts during the remission of IgG4 disease. The authors previously showed that a population of circulating plasmablasts is disproportionately expanded in patients with active IgG4-RD.

In this regard, the authors examined whether circulating plasmablasts have profibrotic properties. The experimental data indicated that fibroblasts co-cultured with plasmablasts produced significantly more collagen than the control fibroblasts or fibroblasts co-cultured with naïve or memory B cells. However, we must acknowledge that these data do not necessarily reflect the exact contribution of B cells to pancreatic fibrosis because of the use of skin fibroblasts, not pancreatic fibroblasts. Additionally, although the authors strongly suggest that plasmablasts directly contribute to fibrosis in the pathogenesis of IgG4RD, it remains unclear whether the profibroblastic property of plasmablasts is specific for patients with IgG4-RD. In this regard, it would be interesting to examine whether plasmablasts from patients with allergies or asthma have profibroblastic properties.

The next question is why plasmablasts have a stronger profibrotic property than naïve and memory B cells. To elucidate the mechanism, the authors focus on Lysyl oxidase-like 2 (LOXL2) expression in B cells. LOXL2 is an enzyme that promotes the network establishment of collagen fibers in the extracellular matrix. The inhibition of LOXL2 can decrease cell numbers, proliferation, colony formation, and cell growth, induce cell cycle arrest and increase apoptosis. Recent reports have shown that LOXL2 is associated with various types of fibrotic diseases (9).

In the study by Della-Torre E et al., immunohistochemistry data demonstrated abundant LOXL2 expression in B cells infiltrating IgG4-RD tissue. Moreover, the intriguing finding is that plasmablasts from patients with IgG4-RD expressed type I collagen genes. We still have the following question: why do plasmablasts mimic the phenotype of myofibroblasts despite their inherently short lives, irrespective

of the nature of the antigen? To answer this question, additional studies with next-generation sequencing, single-cell sequencing, and DNA methylation sequencing would enable us to better identify the contributing factors to the profibrotic phenotype of plasmablasts.

Despite several limitations in this current study, they provide mechanisms for direct involvement of B cells, in particular plasmablasts, in the tissue fibrosis of patients with IgG4-RD. What about autoantibody mediated effects? Could some of the B cell mediated effects in IgG4-related disease be mediated by autoantibodies? Recently, Shiokawa et al reported laminin 511 as one of the target antigens in autoimmune pancreatitis and the induction of antibodies and pancreatic injury by the immunization of mice with human laminin 511-E8 (10). It is possible that plasmablasts may play an important role in IgG4-related disease both by directed cell-mediated effects and by antigen-specific tissue damage (Figure 1).

In conclusion, the pathophysiology of IgG4-RD is not simple. Therefore, further study is needed to understand how immune cells such as CD4 T cells (including Tfh cells) and B cells orchestrate with target autoantigens in many organs of IgG4-RD. The current data can cause controversy regarding B cell biology in elucidating the mechanism of autoimmune diseases, including IgG4-RD. Thus, the development of B cell biology continues.

References

1. Meng XM, Nikolic-Paterson DJ, Lan HY. Inflammatory processes in renal fibrosis. *Nature Rev Nephrol* 2014;10: 493-503.
2. Akiyama M, Suzuki K, Yamaoka K, Yasuoka H, Takeshita M, Kaneko Y, et al. Number of Circulating Follicular Helper 2 T Cells Correlates With IgG4 and Interleukin-4 Levels and Plasmablast Numbers in IgG4-Related Disease. *Arthritis Rheumatol.* 2015 ;67:2476-2481.
3. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. *Lancet* 2015;385(9976):1460-71.
4. Mattoo H, Mahajan VS, Maehara T, Deshpande V, Della-Torre E, Wallace ZS, et al. Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. *J Allerg Clin Immunol* 2016, 138:825-838.
5. Mouquet H, Musette P, Gougeon ML, Jacquot S, Lemerrier B, Lim A, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. *J Invest Dermatol* 2008;128:2859-69.
6. Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy lead to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-Related systemic disease. *Arthritis and Rheumatism.* 2019; 62:1755-62.
7. Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. *Ann Rheum Dis.* 2015;74:1171-7.
8. Della-Torre E, Rigamonti E, Perugini C, Baghai-Sain S, Sun N, Kaneko N, et al. B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. *J Allergy Clin Immunol.* 2019 Jul 15. pii: S0091-6749(19)30936-4.

9. Puente A, Fortea JI, Cabezas J, Arias Loste MT, Iruzubieta P, Lierena S, et al. LOXL2-A new target in antifibrogenic therapy? *Int J Mol Sci* 2019; 2:20(7) pii: E1634.
10. Shiokawa M, Kodama Y, Sekiguchi K, Kuwada T, Tomono T, Kuriyama K, et al. Laminin 511 is a target antigen in autoimmune pancreatitis. *Sci Transl Med*. 2018 ;10(453).

Figure 1. The contribution of B cells to tissue remodeling and fibrosis

The naïve B cells differentiate into memory B cells and plasmablasts after antigen presentation by follicular dendritic cells. In IgG4-related disease, plasmablasts or memory B cells may play an important role in tissue fibrosis both by indirect or direct collagen production. On the other hand, in normal conditions, these cells might contribute to tissue remodeling.

